
Morepen Laboratories Q1 FY22 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
Yes
Order
N/A
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 2- The company achieved a 50% revenue growth in Q1 FY22, a phenomenal increase from previous quarters.
- Dr. Morepen portfolio is expected to grow to around Rs.1,000 crores in the next two years, indicating strong growth in OTC and medical devices.
- Diagnostics division sales grew 189% this quarter, with an increasing share of the company’s revenue; the division is expected to remain a key growth driver.
- API business growth is steady at 17% with plans to focus on new molecules and products linked to a $40 billion market with expiring patents.
- Medical Devices segment expanding capacity and adding new products, projected to keep growing along with Finished Dosage business recovery (30% growth).
- COVID-driven demand for diagnostic devices may normalize but heightened health awareness is expected to sustain higher usage and sales long-term.
- Overall company poised for continued robust growth fueled by expansion in diagnostics, formulations, and new product launches.
See what Morepen Laboratories management said on margin guidance — free account, 30 seconds.
Fundraise plans
Yes- No immediate plans for new fundraising through equity or debt as the company currently has sufficient cash flows.
- Past preferential allotment was postponed to seek higher prices; discussions with investors are ongoing but no final decisions made.
- The company is open to taking term loans for buildings or other needs if required but has not yet signed any agreements.
- CAPEX for the current year (around Rs.35-40 crores) and investments in Medical Devices (around Rs.20 crores) will be funded through internal accruals.
- Working capital requirements are increasing, and the company may consider local arrangements for working capital financing if needed.
- Management is keen on wealth creation for all shareholders and cautious about undervaluation in any fundraising.
See what Morepen Laboratories management said on order book — free account, 30 seconds.
Capex plans
Yes- Total CAPEX requirement is Rs.178 crores over three years; Rs.35-40 crores expected to be spent in the current year.
- API segment investment of Rs.35-40 crores planned from internal accruals.
- Medical Devices segment to receive around Rs.20 crores investment, also from internal accruals.
- Potential backward integration for intermediate chemicals currently imported from China.
- Additional investment may be needed for new API plant building and machinery; higher CAPEX expected next financial year.
- Open to term loans if required for buildings or working capital but currently relying on internal accruals.
- No major investments planned yet for Sputnik vaccine bulk production; only working capital might be needed.
- Strategic focus on biosimilars and new biological products with expansions aligning to these areas.
Track Morepen Laboratories — get its next earnings analysis in your feed
How does Morepen Laboratories rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Morepen Laboratories rank in Pharmaceuticals & Biotechnology?
Compare Morepen Laboratories against every Pharmaceuticals & Biotechnology company (Q1 FY22) on revenue, margins and earnings-call signals.
Continue your research
What Morepen Laboratories's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lasa Supergeneri (Q2 FY27)
306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem